Mortality after deferral of treatment or no treatment for choroidal melanoma

Bradley R Straatsma, Marie Diener-West1, Robert Caldwell, Robert E Engstrom Jr,
For The Collaborative Ocular Melanoma Study Group*

Purpose: To report mortality of patients who were eligible for enrollment in the Collaborative Ocular Melanoma Study (COMS) clinical trials of medium-sized choroidal melanoma or large-sized choroidal melanoma but chose to defer treatment or receive no melanoma treatment. Design: Prospective nonrandomized multicenter cohort study as an adjunct to COMS randomized clinical trials. Methods: Patient follow-up procedures included examinations, correspondence, telephone contacts, and National Death Index searches. Primary outcome was patient death measured by all-cause mortality. Secondary outcomes were melanoma treatment and melanoma metastasis. Results: Of 77 patients eligible for COMS clinical trials who chose to defer or receive no melanoma treatment, 61 were appropriate candidates and 45 (74%) enrolled in the natural history study (NHS). In all, 42 patients (42 eyes) had medium melanoma, and the median follow-up was 5.3 years (range, 4–10.7 years). In all, 22 patients (52%) had subsequent melanoma treatment, and 20 (48%) had no melanoma treatment. For the 42 patients, Kaplan–Meier estimate of 5-year mortality was approximately 30% [95% confidence interval (CI), 18%–47%]. For COMS medium melanoma trial, 5-year mortality was 18% (95% CI, 16%–20%), not statistically significantly different from the NHS patients. After adjusting for differences in age and longest basal diameter, the 5-year risk of death for NHS patients versus COMS trial patients was 1.54 (95% CI, 0.93–2.56). Three patients had large melanoma. Melanoma metastasis was confirmed or suspected in 8 (42%) of 19 deaths. Conclusion: Greater mortality and higher risk of death for NHS patients are prohibitive but not conclusive evidence of a beneficial, life-extending effect of medium melanoma treatment.

Key words: Choroidal melanoma, COMS, melanoma, mortality, uveal melanoma

For more than a century, choroidal melanoma has been recognized as a primary intraocular cancer. Reports by Fuchs and others[1] in the 19th century established enucleation as the accepted treatment. In 1939, Weve[2] reported destruction of the melanoma with diathermy. In the second half of the 20th century, therapy of choroidal melanoma by globe-conserving treatments including radiation therapy, photocoagulation, local excision, and transpupillary thermotherapy were widely reported.[2‑13]

Throughout this period of more than 100 years, diagnosis of choroidal melanoma was associated with treatment. Only case reports or small series were considered cases of choroidal melanoma in which treatment was deferred or declined.[14,15]

When the Collaborative Ocular Melanoma Study (COMS) commenced in 1985, the planning group identified a scarcity of information regarding the natural history of choroidal melanoma. However, a clinical trial of medium-sized or large choroidal melanoma in which some patients received no treatment was judged to be manifestly unethical. Nonetheless, the planners recognized that some patients, confronted with the diagnosis of cancer, elect to defer or decline definitive treatment. From the outset of COMS, information was assembled, as a natural history study (NHS), on patients who were eligible for COMS trials but chose to defer treatment or receive no treatment. This article reports the mortality rate among patients who agreed to follow-up in the NHS.

Materials and Methods

The NHS is a prospective, nonrandomized multicenter cohort study conducted as an adjunct to COMS randomized trials of iodine-125 brachytherapy versus enucleation for medium-sized melanoma.
choroidal melanoma and pre-enucleation radiation versus enucleation for large-sized choroidal melanoma.

COMS design and methods have been published. Aspects relevant to the evaluation and follow-up of COMS-eligible patients who deferred treatment or had no treatment for choroidal melanoma are noted hereafter.

Patients were evaluated at 43 COMS clinical centers in the United States and Canada. All patients for whom the diagnosis of choroidal melanoma was confirmed clinically by a COMS-certified ophthalmologist during the enrollment period from November 1986 to July 31, 1998 were reported to COMS Coordinating Center (Baltimore, MD, USA). Diagnosis of choroidal melanoma was based on a brief medical and ocular history in addition to a comprehensive ophthalmic examination that addressed eligibility for COMS clinical trials and provided baseline descriptive information. Procedures included best-corrected visual acuity, description of melanoma size and location, A-scan and B-scan echograms, fundus photography, and fluorescein angiography. An oncologist or an internist elicited a detailed medical history, performed a cancer-oriented physical examination, and evaluated laboratory studies, chest radiograph, and, where appropriate, imaging or biopsy of the liver or other organs to rule out metastasis or other primary cancer.

To be eligible for COMS randomized medium choroidal melanoma (iodine-125 brachytherapy) clinical trial, the patient had to have a choroidal melanoma measuring from 2.5 to 10.0 mm in apical height and no more than 16.0 mm in longest basal diameter. (From November 1986 until November 1990, tumors 8.0–10.0 mm in apical height also were eligible for this clinical trial.) Throughout enrollment, patients with peripapillary choroidal melanoma (with a border 2.0 mm or less from the optic disk) greater than 8.0 mm in apical height were eligible.

General eligibility requirements were the same as the requirements for COMS medium choroidal melanoma clinical trial. To be eligible for the NHS, patients had to fulfill all requirements for enrollment in the medium choroidal melanoma or large choroidal melanoma clinical trial but (1) did not enroll (reported to COMS Coordinating Center) and (2) chose to receive no treatment for choroidal melanoma. Patients who declined treatment but subsequently received melanoma treatment within 45 days of COMS eligibility were excluded from the NHS.

The NHS protocol and patient consent forms were approved by the Human Subject Protection Committee at UCLA School of Medicine and by the Institutional Review Board of participating institutions. COMS Coordinating Center notified the NHS Coordinating Center (Los Angeles, CA, USA) of the study, identifying numbers and name codes of eligible patients who declined enrollment in a COMS trial and refused initial treatment. The NHS Coordinating Center communicated with COMS clinical centers, which solicited patient participation in the NHS. Patients who enrolled in the NHS signed an approved consent form that permitted periodic follow-up. Patients were identified only by study numbers and name codes assigned at the local clinical center. Follow-up procedures included examinations, correspondence, telephone contacts, and, when appropriate, searches of the National Death Index database. Information was collected on dates of subsequent treatment for choroidal melanoma as well as diagnosis and treatment for metastatic disease. For a patient who died, hospital and laboratory reports and histopathologic materials, when available, were reviewed by COMS Mortality Coding Committee to determine the metastatic status of the patient at the time of death.

The characteristics of patients enrolled and not enrolled in the NHS were compared. Similarly, the characteristics of NHS patients with medium tumors and patients enrolled in COMS medium tumor trial were also compared. Chi-square statistic was used to compare distributions of categorical variables. Survival estimates and associated 95% confidence intervals (CIs) were calculated using Kaplan–Meier method. Cox proportional hazards modeling was performed to investigate the association between survival and treatment and baseline demographic and tumor characteristics. Treatment for choroidal melanoma was handled as a time-dependent covariate.

Results

A total of 777 patients were reported to COMS Coordinating Center as eligible for a COMS clinical trial but did not enroll and chose to receive no melanoma treatment. Of these, three patients were lost to follow-up shortly after COMS eligibility. Three patients received melanoma treatment within 45 days of eligibility and 10 were unsuitable (because of patient mental status, patient ineligibility, or inappropriate reporting) for enrollment in NHS; these patients were considered ineligible for NHS. In all, 45 (74%) of 61 remaining patients enrolled in the NHS and agreed to periodic follow-up. There was no
Fourteen of the 22 medium melanoma patients had died: 5 (23%) by 1.0 years, 7 (32%) by 2.0 years, and 9 (44%) by 5.0 years, respectively. Twenty (48%) of the 42 patients had no melanoma treatment and were followed up for a mean ± SD of 5.4 ± 3.4 years (median, 5.1 years; range, 0.1–10.7 years).

Based on time since COMS eligibility, vital status was known at 5 and 10 years for 32 and 20 of the 42 NHS medium melanoma patients, respectively; Kaplan–Meier estimate of 5-year mortality was approximately 30% (95% CI, 18%–47%; Fig. 1). A total of 16 medium melanoma patients had died: 7 (44%) of the 16 patients had deferred melanoma treatment and 9 (56%) had no melanoma treatment. After accounting for treatment as a time-dependent covariate, there was no clinically or statistically significant difference in mortality between groups defined by deferred treatment versus no treatment (risk ratio = 1.28; 95% CI, 0.50–3.31). Similarly, none of the baseline characteristics, other than age of the patient, was significantly correlated with decreased survival.
A comparison of overall time to death for NHS medium melanoma patients versus COMS patients in the medium tumor trial is shown in Fig. 2. The unadjusted risk ratio for death was 1.79 (95% CI, 1.08–2.97). After adjusting for baseline age and longest basal diameter, the adjusted risk ratio was 1.54 (95% CI, 0.93–2.56).

Three NHS patients (three white men, age 71, 78, and 86 years) had large melanoma. Two patients had melanoma treatment (enucleation) 48 and 73 days after COMS eligibility and were observed until death at 1.5 and 4 years, respectively. Patient 3 had no melanoma treatment and was followed up until death at 12.1 years. Because only three NHS patients had large melanoma, findings were not compared with the demographic and tumor characteristics for the 1,003 patients enrolled in COMS large melanoma trial.[19–21]

All 19 deaths (16 patients with medium melanoma and 3 patients with large melanoma) were reviewed and classified by COMS Mortality Coding Committee[23] as shown in Table 3; 4 deaths with histopathologic confirmation of melanoma metastasis, 2 had a malignant tumor (source of metastasis uncertain), 2 had another tumor, 2 had no evidence of metastasis, and 9 had insufficient information to support presence or absence of metastasis. Melanoma metastasis was confirmed histopathologically or suspected in 6 (32%) of the 19 deaths (5 medium and 1 large); clinical diagnosis of melanoma metastasis was established by imaging or other tests in an additional 2 medium tumor cases, totaling 8 (42%) cases of metastasis in 19 deaths.

**Discussion**

The NHS presents long-term follow-up of patients who were eligible for COMS clinical trials for medium-sized or large choroidal melanoma but who deferred treatment or had no melanoma treatment. Three strengths of the study are evident. First, the NHS study was conducted in conjunction with COMS; hence, collection and recording of patient demographic data, ophthalmic examination information, and general medical examination results were performed in a uniform and consistent manner.

Second, COMS ophthalmologists, photographers, echographers, and other personnel completed certification and recertification procedures. Periodic monitoring by extramural site visitors provided assurance of quality control throughout the years of the study. Diagnosis of melanoma was made in every case by a COMS-certified ophthalmologist on the basis of all available information. Consequently, patient data were reliable, and accuracy of melanoma diagnosis was enhanced.

Third, the high degree of accuracy of melanoma diagnosis by COMS ophthalmologists was verified by histopathology of eyes enucleated in the COMS clinical trials. COMS Pathology Review Committee received histopathologic sections for evaluation from all eyes assigned to enucleation. Clinical diagnosis of choroid melanoma was confirmed by histopathology in 1,527 (99.7%) of 1,532 eyes assigned to enucleation.[25] Because of randomization, 99.7% accuracy of diagnosis may be attributed to patients who underwent brachytherapy and reasonably assumed for patients who were
eligible for COMS clinical trials but chose to defer or decline melanoma treatment.

With these strengths, use of COMS eligibility as a criterion for participation in NHS provided an optimal foundation for assessment of choroidal melanoma natural history. Furthermore, use of COMS eligibility as a criterion for NHS eligibility enabled reasonable comparison between outcomes of untreated and treated choroidal melanoma patients.

Limitations of NHS relate to the relatively small number of patients and the fact that this group was “self-selected” and not randomized. In addition, patients who elected to defer or decline treatment for melanoma often elected to have minimal or no contact with physicians. Consequently, information from the subset of 45 patients who enrolled in NHS and agreed to follow-up is incomplete. Even with these limitations, natural history information on 45 patients is greater than any previous report on survival following delayed treatment or no treatment of choroidal melanoma.[14,15]

Clinically relevant inferences of this study relate to mortality of NHS patients and the comparison of this outcome with mortality of COMS clinical trial participants. In NHS, the 42 patients with medium melanoma who deferred treatment or received no treatment had a 5-year mortality of 30% (95% CI, 18%–47%). Although there was substantial variation in survival among these 42 patients, this estimate of mortality may be a useful guide in counseling patients who have medium melanoma and additional life-threatening medical conditions.

In a comparison of outcome, the 1,317 patients in COMS medium melanoma trial who received protocol treatment had a 5-year mortality of 18% (95% CI, 16%–20%).[23] at the lower boundary of 95% CI for NHS patients and not a statistically significant difference.

Overlapping 95% CIs may have stemmed from the discrepant sample sizes. The relatively small sample of 42 NHS patients resulted in reduced power to detect a statistically significant difference. Post hoc estimate of power to detect a statistically significant difference between 18% and 30% (a difference of 12%) was only 44%, but there was an 80% power to detect a difference of 20% or more.

With regard to other factors that may have affected the comparison of outcome, NHS patients were older than patients in COMS medium melanoma trial, had a longer interval between melanoma diagnosis and eligibility, and had somewhat smaller sized melanomas at the time of COMS eligibility. After adjusting for baseline age and the longest basal diameter of the melanoma, the adjusted risk ratio for death in NHS versus COMS patients was 1.54 (95% CI, 0.93–2.56). With this analysis, age and tumor size may have influenced 5-year mortality, but the net effect and its direction cannot be estimated.

Taken together, the greater mortality and higher relative risk of death for NHS patients are evidence that tends to prove the beneficial life-extending effect of medium melanoma treatment. Although the evidence is probative and not conclusive, it forms a reasonable basis for recommending ocular treatment of medium melanoma. Moreover, the similarity of 5-year outcome emphasizes the need for long-term follow-up (5 years or more) to determine the efficacy of melanoma treatment by any means.

In NHS, the component of all-cause mortality related to metastatic melanoma is difficult to establish, because information from records at time of death or autopsy is not complete for all patients. However, COMS Mortality Coding Committee reviewed all available information for the 16 and 3 deaths in NHS medium and large tumor patients, respectively [Table 3]. Melanoma metastasis was confirmed or suspected histologically in 6 deaths (5 medium and 1 large) and diagnosed premortem in 2 additional medium tumor cases, totaling 8 (42.1%) cases of metastasis in 19 deaths. Fewer than half of the decedents in each group were judged to have melanoma metastasis at time of death, but over half of the patients with premortem melanoma metastasis were judged to have died from confirmed or suspected melanoma metastasis.

Mortality coding, similar 5-year mortality for treated and not treated medium melanoma, and calculations of tumor doubling time suggest that metastatic dissemination may occur at an early stage of choroidal melanoma.[27,31] If metastasis has occurred, ocular treatment will control the ocular tumor but have no effect on the growth of metastatic tumors or long-term survival.

To increase long-term survival, ocular treatment of choroidal melanoma must be combined with measures to detect and treat micrometastasis. Illustrating an approach to detection of micrometastasis, Eide et al. recently reported a prospective study of uveal melanoma patients in whom bone marrow aspirates, studied with the immunomagnetic rosette method, detected tumor cells in 47 (28.7%) of 161 patients. (Eide N, Overgaard R, Jebsen P, et al. Evaluation of 9.2.27 melanoma antibody in micrometastases in malignant uveal melanoma and a comparison of the test results in the eye tumor, the bone marrow and peripheral blood. Presented at the Jules Gonin Club meeting, September 1, 2002.) Treatment of occult micrometastasis is burdened by the limited understanding of fundamental factors that initiate and control the metastatic process in uveal melanoma.[32] However, promising research in this area is directed to (1) genomic study of aberrations in chromosomes 3, 6, and 8[33–35] and investigation of tumor suppressor genes; (2) proteomic research to discover products of tumor suppressor genes and evaluate the metalloproteinases;[36] and (3) immunotherapeutic strategies to enhance melanoma-specific cytotoxic response.[37,38]

In summary, 42 of 45 NHS patients had medium melanoma with an all-cause 5-year mortality of 30% (95% CI, 18%–47%). In comparison, 1,317 patients in the COMS medium melanoma trial had an all-cause 5-year mortality of 18% (95% CI, 16%–20%), a difference that was not statistically significant. After adjustment for patient age and tumor size, the relative risk of death for NHS medium melanoma patients was approximately 50% higher than COMS medium melanoma trial patients (risk ratio = 1.54; 95% CI, 0.93–2.56). Greater mortality and higher 5-year death rate of NHS patients are probative although not conclusive evidence of a life-extending benefit of treatment for medium choroidal melanoma. Among 19 deaths in NHS (16 medium, 3 large), melanoma metastasis was confirmed or suspected in 8 (42%) of 19 deaths. To increase long-term survival, there is a need to combine ocular treatment of choroidal melanoma with measures to detect and treat micrometastatic disease.
Financial support and sponsorship
This study was supported by the National Eye Institute and the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, and Research to Prevent Blindness, New York, New York.

Conflicts of interest
There are no conflicts of interest.

References
1. Fuchs E. Das Sarkom des Uvealtractus. Wien: Wilhelm Braunmüller; 1882. After Reese AB. Tumors of the Eye. New York: Harper and Row; 1963.
2. Weve H. On diathermy in ophthalmic practice. Trans Ophthalmol Soc UK 1939;59:43-80.
3. Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol 1966;50:147-55.
4. Lommatzsch PK. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol 1974;19:85-100.
5. Davidorf FH, Makley TA, Lang JR. Radiotherapy of malignant melanoma of the choroid. Trans Am Acad Ophthalmol Otolaryngol 1976;81:849-61.
6. Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine-125. Ophthalmology 1980;87:582-90.
7. Gragoudas ES, Goitein M, Verhey L, Munzenreider J, Urie M, Suit H, et al. Proton beam irradiation of uveal melanoma (results of a 5 1/2 year study). Arch Ophthalmol 1982;100:928-34.
8. Char DH, Saunders W, Castro JR, Quivey JM, Irvine AR, Stone RD, et al. Holmium ion therapy for choroidal melanoma. Ophthalmology 1983;90:1219-25.
9. Shields JA, Augsburger JJ, Brady LW, Day JL. Cobalt plaque therapy of posterior uveal melanoma. Ophthalmology 1982;89:1201-7.
10. Meyer-Schwickerath, G. The preservation of vision by treatment of intraocular tumors with light coagulation. Arch Ophthalmol 1961;66:36-44.
11. Boniuk M, Girard LJ. Malignant melanoma of the choroid treated with photoagulation, transscleral diathermy and implanted radon seeds. Am J Ophthalmol 1965;59:212-6.
12. Fouls WS, Damato BE. Alternatives to enucleation in the management of choroidal melanoma. Aust NZ J Ophthalmol 1986;14:19-27.
13. Shields CL, Shields JA, Perez N, Singh AD, Cater J. Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases. Ophthalmology 2002;109:225-34.
14. Saraux H, Belosse B. Histoire naturelle des mélanomes malins de la choroïde. J Fr Ophtalmol 1988;11:169-75.
15. Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol 1993;111:1382-16.
16. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition (the Collaborative Ocular Melanoma Study. COMS report no. 3). Control Clin Trials 1993;14:362-91.
17. Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures, PB95–179693. Springfield, VA: National Technical Information Service; 1995.
18. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West, M, McLaughlin JA, for the collaborative ocular melanoma study research group. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology 1998;95:1000-4.
19. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, I (characteristics of patients enrolled and not enrolled. COMS report no. 9). Am J Ophthalmol 1998;125:767-78.
20. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, II (initial mortality findings. COMS report no. 10). Am J Ophthalmol 1998;125:779-96.
21. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, III (local complications and observations following enucleation: COMS report no. 11). Am J Ophthalmol 1998;126:362-72.
22. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II (characteristics of patients enrolled and not enrolled. COMS report no. 17). Arch Ophthalmol 2001;119:951-65.
23. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III (initial mortality findings. COMS report no. 18). Arch Ophthalmol 2001;119:969-82.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
26. Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanoma in eyes enucleated from the collaborative ocular melanoma study. COMS report no. 6. Am J Ophthalmol 1998;125:745-66.
27. Laquis SJ, Freeman JM, Fleming JC, Wilson MW, Haik BG. A rapid growing choroidal melanoma. Am J Ophthalmol 2002;133:580.
28. Friberg TR, Fineberg E, McQuaig S. Extremely rapid growth of a primary choroidal melanoma. Arch Ophthalmol 1983;101:1375-7.
29. Manschot WA. The natural history of uveal melanomas and its therapeutic consequences. Doc Ophthalmol 1980;50:83-99.
30. Manschot WA, Lee WR, van Strik R. Uveal melanoma: Updated considerations on current management modalities. Int Ophthalmol 1995–96;19:203-9.
31. Eskelin S, Pyrhönen S, Summanen P, Hakka-Kempinnen M, Kivelä T. Tumor doubling time in metastatic malignant melanoma of the uvea. Ophthalmology 2000;107:1443-9.
32. Rennie I. Melanomas, metastases, and survival. (Editorial). Br J Ophthalmol 1993;77:685-7.
33. Sidey K, Rennie IG, Cottam DW, Potter AM, Potter CW, Rees RC. Cytogenetic findings in six posterior uveal melanomas. Genes Chrom Cancer 1990;2:205-9.
34. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-9.
35. Sidey K, Cottam DC, Rennie IG, Parsons MA, Potter AM, Potter CW, et al. Non-random abnormalities of chromosomes 3, 6 and 8 associated with posterior uveal melanoma. Genes Chrom Cancer 1992;5:197-200.
36. Cottam DW, Rennie IG, Woods K, Parsons MA, Bunning RAD, Rees RC. Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Ophthalmol Vis Sci 1992;33:1923-27.
37. Frost PH, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. J Immunol 2001;166:3564-73.
38. Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, et al. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res 2000;60:2218-24.